The idea will give cold sweats to any investor familiar with Theranos Inc. That company, too, aimed to run large numbers of tests on small amounts of blood. It didn’t work, and its founder, Elizabeth Holmes, is currently serving 11 years in prison for fraud after the company rode a $9 billion valuation down to zero.
Vital Biosciences and its backers are aware of the parallels. “In some ways, it makes it more intriguing,” said investor
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.